[go: up one dir, main page]

ES454120A1 - Procedimiento para la obtencion de polihalogenoesteroides. - Google Patents

Procedimiento para la obtencion de polihalogenoesteroides.

Info

Publication number
ES454120A1
ES454120A1 ES454120A ES454120A ES454120A1 ES 454120 A1 ES454120 A1 ES 454120A1 ES 454120 A ES454120 A ES 454120A ES 454120 A ES454120 A ES 454120A ES 454120 A1 ES454120 A1 ES 454120A1
Authority
ES
Spain
Prior art keywords
alpha
beta
polyhalogeno
steroids
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES454120A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25717430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES454120(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1615175A external-priority patent/CH621801A5/de
Priority claimed from LU75903A external-priority patent/LU75903A1/xx
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES454120A1 publication Critical patent/ES454120A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para la obtención de polihalógeno-esteroides, concretamente de compuestos 9alfa, 21-dihalógeno-11beta, 17alfa-dihidroxi-6alfa-flúor-16alfa-metil-pregna-1,4-dien-3, 20-diona de fórmula **(Fórmula)** donde X1 significa cloro o flúor, X2 significa bromo o cloro, R1 significa hidrógeno o cloro y R2 significa hidrógeno o el resto acilo Ac de un ácido carboxílico, o las sales de tales compuestos con propiedades formadoras de sal.
ES454120A 1975-12-12 1976-12-10 Procedimiento para la obtencion de polihalogenoesteroides. Expired ES454120A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1615175A CH621801A5 (en) 1975-12-12 1975-12-12 Process for the preparation of polyhalosteroids
LU75903A LU75903A1 (es) 1976-09-29 1976-09-29

Publications (1)

Publication Number Publication Date
ES454120A1 true ES454120A1 (es) 1978-02-16

Family

ID=25717430

Family Applications (1)

Application Number Title Priority Date Filing Date
ES454120A Expired ES454120A1 (es) 1975-12-12 1976-12-10 Procedimiento para la obtencion de polihalogenoesteroides.

Country Status (16)

Country Link
US (1) US4619921A (es)
JP (1) JPS5289662A (es)
AT (2) AT357703B (es)
AU (1) AU508224B2 (es)
CA (1) CA1056371A (es)
DD (1) DD128683A5 (es)
DE (1) DE2655570A1 (es)
DK (1) DK143708C (es)
ES (1) ES454120A1 (es)
FR (1) FR2334363A1 (es)
GB (1) GB1537130A (es)
HU (1) HU175583B (es)
IE (1) IE44473B1 (es)
IL (1) IL51087A (es)
NL (1) NL7613791A (es)
NZ (1) NZ182836A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209140B (it) * 1979-11-16 1989-07-10 Prochem Ets 6 alfa-fluoro-prednisolone 17,21-diesteri.
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.
EP1465855A2 (en) 2001-11-29 2004-10-13 Taro Pharmaceuticals U.S.A., Inc. Method for the production of 6-alpha-fluoro corticosteroids
US20040138192A1 (en) * 2003-01-13 2004-07-15 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2006110534A2 (en) * 2005-04-07 2006-10-19 Taro Pharmaceuticals U.S.A., Inc. A process for preparing a crystalline form of halobetasol propionate
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプｉｖ阻害剤の組成物
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US8420666B2 (en) 2007-03-14 2013-04-16 Ranbaxy Laboratories Limited Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
US10251895B2 (en) 2015-06-18 2019-04-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating psoriasis
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL241055A (es) * 1958-07-09
US3499016A (en) * 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
GB898292A (en) * 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH534144A (de) * 1967-11-17 1973-02-28 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
US3718673A (en) * 1971-02-01 1973-02-27 Du Pont Process for the preparation of 21-chloro-6,6,9alpha-trifluoro-11beta, alpha, 17alpha-trihydroxy-1,4-pregnadien-3,20-dione 16,17-ketals and selected intermediates
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes

Also Published As

Publication number Publication date
FR2334363A1 (fr) 1977-07-08
IL51087A0 (en) 1977-02-28
DK143708C (da) 1982-03-15
US4619921A (en) 1986-10-28
HU175583B (hu) 1980-09-28
GB1537130A (en) 1978-12-29
JPS5289662A (en) 1977-07-27
ATA913976A (de) 1979-12-15
AT357703B (de) 1980-07-25
NZ182836A (en) 1979-01-11
DE2655570A1 (de) 1977-06-16
AU508224B2 (en) 1980-03-13
DK557876A (da) 1977-06-13
DD128683A5 (de) 1977-12-07
ATA81279A (de) 1980-12-15
DK143708B (da) 1981-09-28
AU2047276A (en) 1978-06-15
FR2334363B1 (es) 1980-03-14
CA1056371A (en) 1979-06-12
IE44473B1 (en) 1981-12-16
IL51087A (en) 1980-06-30
AT363201B (de) 1981-07-27
IE44473L (en) 1977-06-12
NL7613791A (nl) 1977-06-14

Similar Documents

Publication Publication Date Title
ES454120A1 (es) Procedimiento para la obtencion de polihalogenoesteroides.
ES417012A2 (es) Mejoras introducidas en el objeto de la patente principal, num. 399.057.
DK73594A (da) Fremgangsmåde til fremstilling af 17-substituerede 4-aza-5,7-androstadien-3-on-derivater
CY544A (en) 17beta -Monoesters of 11,17,21-trihydroxy steroid compounds
ES463633A1 (es) Procedimiento de preparacion de derivados de la piperidina.
DK396284D0 (da) 17beta-methoxycarbonylderivater af androstan-raekken samt deres fremstiling og anvendelse
ES452737A1 (es) Un procedimiento para preparar compuestos 2-anol-3-fenilben-zotiofeno.
DK158358C (da) 1-substituerede androsta-1,4-dien-3,17-dioner og farmaceutiske praeparater indeholdende dem
ES8704967A1 (es) Procedimiento para la obtencion de un 9alfa, 11alfa-epoxiesteroide.
AP9300589A0 (en) Novel 17a and 17b substituted acyl-3-carboxy 3,5-diene steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-a-reductase.
ES455133A1 (es) Un procedimiento de preparacion de 17-esteres de 17-alfa-hi-droxi-gestogenos.
IL56973A0 (en) Pharmaceutical compositon containing steroids of the corticoid series preparation of such steroids and certain novel compounds of this type
GB1513383A (en) Pharmaceutical compositions
GB1218858A (en) Improvements in or relating to refractory compositions
GB1532046A (en) Glass
GB1187660A (en) Fluoroformates of Steroid 17-beta-Ols
GB1427131A (en) Quaternary compounds of benzene derivatives and their use as sun-screening agents
ES344167A1 (es) Procedimiento de preparacion de nuevos 4-halogen-1,2 alfa; 6,7 beta-bismetilen-delta4-3-cetoesteroides.
ES432414A1 (es) Procedimiento de preparacion de alfa-acetoglutarato de vin-camina.
GB1274033A (en) NOVEL 1-OXA-5alpha,17beta-DIHYDROXY-9alpha-HALO-13beta-ALKYL-17alpha-METHYL-A-NOR-10alpha-GONAN-2-ONES, AND PROCESSES FOR THEIR PREPARATION
GB1272688A (en) Sulphamido-steroids and the preparation thereof
ES469513A1 (es) Procedimiento para preparar nuevos derivados de pregn-4-eno.
GB1154407A (en) Novel 9beta,10alpha-Steroids
AU291165B2 (en) 17a-MONOESTERS OF 11, 17, 21-TRIHYDROXY STEROID COMPOUNDS
AU247661B2 (en) Steroid compounds for use in the synthesis of 9 a-fluoro-1 b, 17 a, 21-trihydroxy-16 a-methyl-pregna-1, 4-dien-3, 20-dione, processes for preparation thereof and for their conversion

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19990503